Colorectal Cancer and Gut Health: Expert Insights from Dr. Richard Birkett

    BOSTON, MA, August 28, 2024 /24-7PressRelease/ -- The likelihood of developing colorectal cancer increases with age, particularly for individuals over 50. Symptoms such as diarrhea, constipation, blood in the stool, abdominal pain, unexplained weight loss, fatigue, and low iron levels are common indicators. However, early-stage colorectal cancer often presents without noticeable symptoms, making regular screenings vital for early detection.

Preventative measures include maintaining a healthy diet, staying physically active, avoiding smoking, limiting alcohol consumption, and undergoing regular screenings. Globally, colorectal cancer is the second leading cause of cancer-related deaths, with over 1.9 million new cases and more than 930,000 deaths reported in 2020. The highest incidence rates are observed in Europe, Australia, and New Zealand, while Eastern Europe has the highest mortality rates. Future projections indicate a troubling rise, with cases expected to reach 3.2 million annually by 2040, accompanied by 1.6 million deaths per year.

Colorectal cancer is increasingly becoming a significant concern, particularly among younger populations. Recent data indicates a troubling rise in colorectal cancer diagnoses in individuals under 50. Addressing this critical health issue, Dr. Richard Birkett, a highly skilled colorectal, general, and trauma surgeon based in Greater Boston, offers his expertise and insights into colorectal cancer, gut health, and the importance of early screening.

Colorectal cancer is no longer confined to older adults. Recent statistics reveal a sharp increase in cases among younger individuals. In the United States, approximately 10% of colorectal cancer cases are diagnosed in people under 50. Moreover, the incidence of young-onset rectal cancer is rising nearly twice as fast as young-onset colon cancer. Researchers predict that by 2030, colorectal cancer will be the leading cause of cancer deaths among people aged 20-49.

Dr. Richard Birkett, an expert in laparoscopic and robotic surgery with a focus on GI oncology, GI immunologic diseases, benign diseases of the GI tract, and perioperative physiology, emphasizes the critical importance of early detection and regular screenings. With both an MD and MBA, Dr. Birkett's expertise also extends to medical device marketing, product development, business development, and evaluation. His experience in developing and executing Sustainability/ESG programs in healthcare and the device industries further enhances his holistic approach to patient care and advocacy.

"In light of the increasing prevalence of colorectal cancer in younger adults, prioritizing early detection and regular screenings is crucial," says Dr. Birkett. "The guidelines for colorectal cancer screening have recently changed, lowering the recommended starting age to 45 for average-risk individuals. This change is a direct response to the alarming rise in diagnoses among younger people."

The United States Preventive Services Task Force (USPSTF) now recommends that all individuals at average risk begin colorectal cancer screening at age 45. Those at higher risk may need to start earlier. Factors such as ethnicity, lifestyle, and family history can influence when an individual should get screened. It is essential to discuss personal risk factors with a healthcare provider to determine the appropriate screening schedule.

While colonoscopy is considered the gold standard, several screening methods are available. The choice of test depends on age, personal health history, and family background. Starting at age 45 (if at average risk), individuals can choose from stool tests such as FIT, stool-DNA testing (e.g., Cologuard), and FOBT, or visual exams like colonoscopy, virtual colonoscopy, and flexible sigmoidoscopy. Healthcare providers can guide patients in selecting the best screening method for their needs.

You are considered at average risk if you have no symptoms, no family history of colorectal cancer, no personal history of cancer or certain types of polyps, no genetic links to Lynch syndrome, FAP, or other genetic conditions, and no personal history of ulcerative colitis, inflammatory bowel disease, or Crohn's disease. The standard screening age of 45 applies to those at average risk, but those at higher risk may need to start screening earlier.

The primary hereditary conditions associated with colorectal cancer include Lynch Syndrome, Muir-Torre Syndrome (MTS), MUTYH-Associated Polyposis Syndrome (MAP Syndrome), Familial Adenomatous Polyposis (FAP), Peutz-Jeghers Syndrome, and Li-Fraumeni Syndrome.Screening is crucial for early detection and prevention of colorectal cancer. Discuss your genetic risk with your healthcare provider to develop a personalized screening plan.

The treatment for colorectal cancer depends on the cancer's type, stage, and the patient's overall health. Early detection often leads to better treatment options and outcomes. Treatment options include surgery, typically used in the early stages when the cancer is localized, radiotherapy to shrink tumors before surgery or target cancer cells, chemotherapy to kill or inhibit cancer cells, targeted therapy focusing on specific molecules involved in cancer growth, and immunotherapy to stimulate the body's immune system to recognize and attack cancer cells.

A multidisciplinary approach, involving a team of specialists from various fields, ensures comprehensive care, while supportive care focuses on symptom management, emotional support, and enhancing the overall quality of life for patients and their families.

About Richard Birkett, MD, MBA

Dr. Richard Birkett is a distinguished Colon and Rectal Surgeon, recognized for his expertise in minimally invasive robotic and laparoscopic surgery. Practicing in Greater Boston, he specializes in treating colon and rectal cancer, diverticulitis, GI immunologic diseases, benign GI tract conditions, and anorectal diseases. His commitment to employing advanced surgical techniques reflects his dedication to enhancing patient outcomes.

With a strong foundation in General and Trauma Surgery, Dr. Birkett approaches patient care with a comprehensive perspective. His academic contributions, including numerous peer-reviewed manuscripts and book chapters, demonstrate his commitment to advancing medical knowledge. As the site director for surgical residents, he is also deeply invested in surgical education and mentorship.

Dr. Birkett's dual qualifications—an MD and an MBA—provide him with unique insights into medical device marketing, product development, business strategy, and Sustainability/ESG programs within healthcare and the medical device industries. His expertise spans team leadership, interdisciplinary collaboration, complex problem-solving, and patient advocacy.

Outside of his professional career, Dr. Birkett is an avid athlete, exemplifying dedication and perseverance. He has completed multiple Ironman races (2012, 2021, 2022) and half Ironmans (2013, 2024). His marathon endeavors include the Boston Marathon (2017) for Plan International and the upcoming NYC Marathon for Camp Shriver, showcasing his commitment to community service through charitable athletic pursuits.

# # #